A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G

Clinical trial NCT06419205 · RECRUITING

Trial details

NCT number: NCT06419205
Sponsor: Akebia Therapeutics
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

IgA Nephropathy Lupus Nephritis (LN)C3 (Complement Component 3) Glomerulopathy

Start date: 2026-07-30
Primary completion: 2028-02-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.